Technical Analysis for AKTX - Akari Therapeutics Plc

Grade Last Price % Change Price Change
grade C 4.57 12.01% 0.49
AKTX closed up 12.01 percent on Monday, March 18, 2019, on 1.14 times normal volume.

Earnings due: Mar 20

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical AKTX trend table...

Date Alert Name Type % Chg
Mar 18 New Uptrend Bullish 0.00%
Mar 18 Calm After Storm Range Contraction 0.00%
Mar 18 Parabolic Rise Strength 0.00%
Mar 18 Upper Bollinger Band Walk Strength 0.00%
Mar 18 Inside Day Range Contraction 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Upper Bollinger Band Touch Strength 0.00%
Mar 15 Wide Range Bar Range Expansion 12.01%
Mar 15 Parabolic Rise Strength 12.01%
Mar 15 Upper Bollinger Band Walk Strength 12.01%

Older signals for AKTX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b – 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.
Medicine Biopharmaceutical Medical Specialties Organ Systems Rare Diseases Autoimmunity Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Myasthenia Gravis Alexion Pharmaceuticals Atypical Hemolytic Uremic Syndrome Complement System
Is AKTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.2
52 Week Low 1.56
Average Volume 2,316,288
200-Day Moving Average 1.9793
50-Day Moving Average 2.138
20-Day Moving Average 2.4804
10-Day Moving Average 3.1299
Average True Range 0.7777
ADX 26.94
+DI 56.7418
-DI 15.2892
Chandelier Exit (Long, 3 ATRs ) 6.866899999999999
Chandelier Exit (Short, 3 ATRs ) 4.0831
Upper Bollinger Band 5.1806
Lower Bollinger Band -0.2198
Percent B (%b) 0.89
BandWidth 217.722948
MACD Line 0.6706
MACD Signal Line 0.3263
MACD Histogram 0.3443
Fundamentals Value
Market Cap 53.81 Million
Num Shares 11.8 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -2.29
Price-to-Sales 0.00
Price-to-Book 2.11
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.91
Resistance 3 (R3) 5.96 5.58 5.68
Resistance 2 (R2) 5.58 5.24 5.55 5.61
Resistance 1 (R1) 5.07 5.03 5.33 5.02 5.53
Pivot Point 4.69 4.69 4.81 4.66 4.69
Support 1 (S1) 4.18 4.35 4.44 4.13 3.61
Support 2 (S2) 3.80 4.14 3.77 3.53
Support 3 (S3) 3.29 3.80 3.46
Support 4 (S4) 3.24